Research programme: PGG glucan antibody conjugate - Biothera

Drug Profile

Research programme: PGG glucan antibody conjugate - Biothera

Alternative Names: Imprime PGG-antibody conjugate

Latest Information Update: 21 Jan 2014

Price : $50

At a glance

  • Originator Biothera
  • Class Beta Glucans; Drug conjugates; Immunoconjugates; Monoclonal antibodies
  • Mechanism of Action Immunostimulants; Macrophage 1 antigen modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Research Cancer

Most Recent Events

  • 16 Jan 2014 Early research in Cancer in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top